Efficacy and safety of Longjintonglin Capsule for the treatment of type Ⅲ prostatitis
SHANG Xue-jun
GENG Qiang
DUAN Jian-min
ZHENG De-quan
XIE Lei
GUO Jun
Abstract：Objective:To study the therapeutic effect and safety of Longjintonglin Capsule in the treatment of type Ⅲ prostatitis (chronic prostatitis / chronic pelvic pain syndrome,CP/CPPS).Method:We selected 240 patients with type Ⅲ prostatitis according to the diagnostic standards of the American National Institute of Health (NIH) and treated them with Longjintonglin Capsule orally 3 capsules once tid for 12 weeks.Based on the NIH chronic prostatitis symptom index (NIH-CPSI),traditional Chinese medicine (TCM) syndrome score,and leukocyte count in the expressed prostatic secretion (EPS),we evaluated the results of treatment.Results:Totally 238 patients completed the treatment,including 108 ⅢA and 120 Ⅲ B prostatitis cases.Before and after 4,8,and 12weeks of treatment,the total NIH-CPSI scores were 23.12 ± 6.99,18.22 ± 6.39,14.12 ± 5.88,and 12.36 ± 6.04 (P ＜ 0.01) in the ⅢA prostatitis patients and 22.01 ±6.28,17.56 ±5.89,13.67 ±5.18,and 11.45 ± 5.22 in the ⅢB prostatitis patients (P ＜ 0.01),the TCM syndrome scores were 52.12 ± 13.08,48.13 ± 12.11,43.05 ± 11.19,and 40.78 ± 10.59 in the former (P ＜ 0.01) and 53.02 ± 12.12,49.32 ± 12.78,44.01 ± 11.79,and 39.67 ± 10.26 in the latter (P ＜ 0.01),and the leukocyte counts were 26.09 ± 21.55,23.02 ± 18.61,18.25 ± 17.79,and 15.36 ± 16.38 in the Ⅲ A cases (P ＜ 0.01).Neither abnormalities in liver and renal function nor obvious adverse events were observed during the experiment.Conclusion:Longjintonglin Capsule,with its advantages of safety,effectiveness,and no obvious adverse reactions in the treatment of type Ⅲ prostatitis,deserves to be recommended for clinical application.
Keywords：type Ⅲ prostatitisLongjintonglin CapsuleNIH-CPSIexpressed prostatic secretionleukocyte
Publication Date：2014-11-16
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)